Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases

We present 2 cases of DIPG, who were treated with panobinostat at 22 to 25 mg/m2/dose, 3 times weekly for 2 weeks in 3-week cycles and concomitant reirradiation after disease progression. Two episodes of asymptomatic thrombocytopenia were observed in 1 patient. Hyperacetylation of histone H4 of peripheral blood mononuclear cells was evident following treatment. In our experience, panobinostat administered with reirradiation was well tolerated at a relatively higher dose than that used in adult studies. (Source: Journal of Pediatric Hematology Oncology)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uysZQi
via IFTTT